Abstract

Mini Review

Required Elements for Next-generation Prognostic Index beyond Left Ventricular Ejection Fraction in Heart Failure

Shiro Hoshida*

Published: 12 August, 2024 | Volume 9 - Issue 2 | Pages: 116-117

Many reports are showing no differences in prognosis between patients with Heart Failure (HF) with preserved and reduced ejection fraction. All-in-one analysis with a multivariable model, including clinical characteristics, blood test, comorbidity, and echocardiographic indices, on clinical outcomes in patients with HF has not been performed rarely in previous studies. We have to accept the need to be more comprehensive in the outcome analysis of patients with HF and consider the intricate interplay of multiple variables in patient outcomes.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001189 Cite this Article Read Full Article PDF

Keywords:

Heart failure; LVEF; Prognostic index

References

  1. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17:559-573. Available from: https://doi.org/10.1038/s41569-020-0363-2
  2. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation. 2016;134:73-90. Available from: https://doi.org/10.1161/circulationaha.116.021884
  3. Omote K, Verbrugge FH, Borlaug BA. Heart failure with preserved ejection fraction: Mechanisms and treatment strategies. Annu Rev Med. 2022;73:321-337. Available from: https://doi.org/10.1146/annurev-med-042220-022745
  4. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574-1585. Available from: https://doi.org/10.1002/ejhf.813
  5. Quiroz R, Doros G, Shaw P, Liang CS, Gauthier DF, Sam F. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol. 2014;113:691-6. Available from: https://doi.org/10.1016/j.amjcard.2013.11.014
  6. Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D, et al. Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: Data from the EMPA-REG OUTCOME trial. J Card Fail. 2021;27:888-895. Available from: https://doi.org/10.1016/j.cardfail.2021.05.012
  7. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. Available from: https://doi.org/10.1056/nejmoa1409077
  8. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-1620. Available from: https://doi.org/10.1056/nejmoa1908655
  9. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. Available from: https://doi.org/10.1056/nejmoa2107038
  10. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-128. Available from: https://doi.org/10.1056/nejmoa2030183
  11. Pandey AK, Dhingra NK, Hibino M, Gupta V, Verma S. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2022;9:942-946. Available from: https://doi.org/10.1002/ehf2.13805
  12. Bayes-Genis A, Pascual-Figal D, Nunez J. The pre-HFpEF stage: a new entity that requires proper phenotyping for better management. Eur J Prev Cardiol. 2021;28:935-936. Available from: https://doi.org/10.1177/2047487320902326
  13. Sotomi Y, Hikoso S, Komukai S, Sato T, Oeun B, Kitamura T, et al. OCVC-Heart Failure Investigator. Phenotyping of acute decompensated heart failure with preserved ejection fraction. Heart. 2022;108:1553-1561. Available from: https://doi.org/10.1136/heartjnl-2021-320270
  14. Burke MA, Katz DH, Beussink L, Selvaraj S, Gupta DK, Fox J, Chakrabarti S, Sauer AJ, Rich JD, Freed BH, Shah SJ. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7:288-299. Available from: https://doi.org/10.1161/circheartfailure.113.000854
  15. Hoshida S, Tachibana K, Shinoda Y, Minamisaka T, Yamada T, Higuchi Y, et al. Osaka Cardiovascular Conference Investigators. Left atrial pressure overload and prognosis in elderly patients with heart failure and preserved ejection fraction: A prospective multicenter observational study. BMJ Open. 2021;11. Available from: https://doi.org/10.1136/bmjopen-2020-044605
  16. Hoshida S. Left-side pressure index for all-cause mortality in older adults with HFpEF: Diagnostic potential for HFpEF and possible view for HFrEF. J Clin Med. 2023;12:802. Available from: https://doi.org/10.3390/jcm12030802
  17. Hoshida S. Due diligence of a diastolic index as a prognostic factor in heart failure with preserved ejection fraction. J Clin Med. 2023;12:6692. Available from: https://doi.org/10.3390/jcm12206692 

Figures:

Similar Articles

Recently Viewed

  • Synthesis of Carbon Nano Fiber from Organic Waste and Activation of its Surface Area
    Himanshu Narayan*, Brijesh Gaud, Amrita Singh and Sandesh Jaybhaye Himanshu Narayan*,Brijesh Gaud,Amrita Singh,Sandesh Jaybhaye. Synthesis of Carbon Nano Fiber from Organic Waste and Activation of its Surface Area. Int J Phys Res Appl. 2019: doi: 10.29328/journal.ijpra.1001017; 2: 056-059
  • Obesity Surgery in Spain
    Aniceto Baltasar* Aniceto Baltasar*. Obesity Surgery in Spain. New Insights Obes Gene Beyond. 2020: doi: 10.29328/journal.niogb.1001013; 4: 013-021
  • Tamsulosin and Dementia in old age: Is there any relationship?
    Irami Araújo-Filho*, Rebecca Renata Lapenda do Monte, Karina de Andrade Vidal Costa and Amália Cinthia Meneses Rêgo Irami Araújo-Filho*,Rebecca Renata Lapenda do Monte,Karina de Andrade Vidal Costa,Amália Cinthia Meneses Rêgo. Tamsulosin and Dementia in old age: Is there any relationship?. J Neurosci Neurol Disord. 2019: doi: 10.29328/journal.jnnd.1001025; 3: 145-147
  • Case Report: Intussusception in an Infant with Respiratory Syncytial Virus (RSV) Infection and Post-Operative Wound Dehiscence
    Lamin Makalo*, Orlianys Ruiz Perez, Benjamin Martin, Cherno S Jallow, Momodou Lamin Jobarteh, Alagie Baldeh, Abdul Malik Fye, Fatoumatta Jitteh and Isatou Bah Lamin Makalo*,Orlianys Ruiz Perez,Benjamin Martin,Cherno S Jallow,Momodou Lamin Jobarteh,Alagie Baldeh,Abdul Malik Fye,Fatoumatta Jitteh,Isatou Bah. Case Report: Intussusception in an Infant with Respiratory Syncytial Virus (RSV) Infection and Post-Operative Wound Dehiscence. J Community Med Health Solut. 2025: doi: 10.29328/journal.jcmhs.1001051; 6: 001-004
  • The prevalence and risk factors of chronic kidney disease among type 2 diabetes mellitus follow-up patients at Debre Berhan Referral Hospital, Central Ethiopia
    Getaneh Baye Mulu, Worku Misganew Kebede, Fetene Nigussie Tarekegn, Abayneh Shewangzaw Engida, Migbaru Endawoke Tiruye, Mulat Mossie Menalu, Yalew Mossie, Wubshet Teshome and Bantalem Tilaye Atinafu* Getaneh Baye Mulu,Worku Misganew Kebede,Fetene Nigussie Tarekegn,Abayneh Shewangzaw Engida,Migbaru Endawoke Tiruye,Mulat Mossie Menalu,Yalew Mossie,Wubshet Teshome,Bantalem Tilaye Atinafu*. The prevalence and risk factors of chronic kidney disease among type 2 diabetes mellitus follow-up patients at Debre Berhan Referral Hospital, Central Ethiopia. J Clini Nephrol. 2023: doi: 10.29328/journal.jcn.1001104; 7: 025-031

Read More

Most Viewed

Read More

Help ?